We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 92

MedyMatch Intracranial Hemorrhage Detection Software Receives Expedited FDA Review
  • Knobbe Martens
  • USA, Israel
  • February 18 2018

Tel Aviv-based MedyMatch Technology recently announced it has received Expedited Access Pathway (EAP) designation from the FDA for its intracranial


Biosimilars in Israel: Substantial Revisions to the Regulatory Scheme
  • Gilat, Bareket & Co., Reinhold Cohn Group
  • Israel
  • June 20 2016

In May 2016, Israel's Ministry of Health ("MoH") published substantial revisions to the guidelines appearing in Procedure No. 127, which regulates


A new policy regarding the registration and use of bio-similar pharmaceuticals in Israel
  • Reinhold Cohn Group
  • Israel
  • June 8 2014

On April 2014, the Israeli Ministry of Health ("MoH") issued a new work procedure, no. 127, which provides for more structured and detailed policy